Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pagel

Showing results (111-120 of 245) with videos related to

Pageof 25
Sort By:
Leukemia & Lymphoma|March 29, 2023
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database studyToby A Eyre, Lisa M Hess, Tomoko Sugihara, et al.
Leukemia & Lymphoma|October 6, 2007
The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantationGrant E Keeney, Ted A Gooley, Rosalyn N Pham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemiaXueyan Chen, Hu Xie, Brent L Wood, et al.
Blood|February 17, 2007
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomasAnastasia Pantelias, John M Pagel, Nathan Hedin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 4, 2014
Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remissionRoland B Walter, Brenda M Sandmaier, Barry E Storer, et al.
The Lancet. Oncology|July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trialJohn M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphomaAjay K Gopal, Ted A Gooley, Joseph G Rajendran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2003
Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenograftsKrishnan Subbiah, Don K Hamlin, John M Pagel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphomaAjay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.
Cancer Research|January 2, 2009
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemiaJohn M Pagel, Dana C Matthews, Aimee Kenoyer, et al.
Pageof 25

Showing results (111-120 of 245) with videos related to

Sort By:
Pageof 25
Leukemia & Lymphoma|March 29, 2023
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database studyToby A Eyre, Lisa M Hess, Tomoko Sugihara, et al.
Leukemia & Lymphoma|October 6, 2007
The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantationGrant E Keeney, Ted A Gooley, Rosalyn N Pham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemiaXueyan Chen, Hu Xie, Brent L Wood, et al.
Blood|February 17, 2007
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomasAnastasia Pantelias, John M Pagel, Nathan Hedin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 4, 2014
Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remissionRoland B Walter, Brenda M Sandmaier, Barry E Storer, et al.
The Lancet. Oncology|July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trialJohn M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphomaAjay K Gopal, Ted A Gooley, Joseph G Rajendran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2003
Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenograftsKrishnan Subbiah, Don K Hamlin, John M Pagel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphomaAjay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.
Cancer Research|January 2, 2009
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemiaJohn M Pagel, Dana C Matthews, Aimee Kenoyer, et al.
Pageof 25